Final Results of Phase I/II Study of Selinexor (SEL) with Sorafenib in Patients (pts) with Relapsed and/or Refractory (R/R) FLT3 Mutated Acute Myeloid Leukemia (AML)
Year: 2018
Type: conference-abstract
Source: Blood
Authors: Naval G. Daver, Rita Assi, Hagop M. Kantarjian, Jorge E. Cortes, Farhad Ravandi, Marina Y. Konopleva, Tapan M. Kadia, Gautam Borthakur, Elias J. Jabbour, Courtney D. DiNardo, Michelle Velasquez, Mary Kelly, Jing Ning, Graciela M. Nogueras González, Sherry A. Pierce, Dan Gombos, Zeev E. Estrov, Steven M. Kornblau, Weiguo Zhang, Michael Andreeff
Institution: The University of Texas MD Anderson Cancer Center
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4205101162